ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effect of Oxytocin and Vasopressin Antagonists on Uterine Contractions (OVANCON)

This study has been completed.

Sponsored by: Ferring Pharmaceuticals
Information provided by: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00587327
  Purpose

The main purpose of this clinical research study is to investigate if barusiban and/or atosiban can reduce the frequency of contractions in the womb at a time when fertilised eggs would be placed in the womb in patients undergoing IVF


Condition Intervention Phase
In Vitro Fertilisation (IVF) Treatment.
Drug: Barusiban
Drug: Atosiban
Drug: Placebo
Phase II

ChemIDplus related topics:   Sodium chloride    Progesterone    Oxytocin    Atosiban    Argipressin    Vasopressins    Barusiban   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   A Randomised, Double-Blind, Parallel Groups, Placebo-Controlled, Multi-Centre Study Assessing the Effects of a Selective Oxytocin Antagonist (Barusiban) and a Mixed Oxytocin Antagonist - Vasopressin V1a Antagonist (Atosiban) Administered Intravenously on Luteal Phase Uterine Contractions in Oocyte Donors Supplemented With Vaginal Progesterone

Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Frequency of uterine contractions at 3 hours after start of dosing. [ Time Frame: 3h after start of dosing ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Period, external, internal, and total contractile measure of uterine contractions. Frequency, period, external, internal, and total contractile measure [ Time Frame: 3h after start of dosing ] [ Designated as safety issue: No ]

Estimated Enrollment:   120
Study Start Date:   November 2007
Study Completion Date:   May 2008
Primary Completion Date:   May 2008 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Barusiban: Experimental Drug: Barusiban
Solution for IV treatment. Bolus and infusion for 4 hours
Atosiban: Experimental Drug: Atosiban
Solution for IV administration. Bolus and infusion for 4 hours
Placebo: Placebo Comparator Drug: Placebo
Saline solution for IV administration. Bolus and infusion for 4 hours.

  Eligibility
Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Oocyte donors 18-35 years of age, who have undergone controlled ovarian hyperstimulation in the long GnRH agonist protocol or the multiple-dose or single-dose GnRH antagonist protocols, have received hCG (≥ 5,000 IU urinary hCG or 250 μg recombinant hCG) for triggering final follicular maturation and have underwent oocyte retrieval with a yield of ≥ 6 cumulus-oocyte-complexes.
  • Generally healthy subjects and with a BMI of 18.5-29.9 kg/m2.

Exclusion Criteria:

  • Subjects are excluded in case of endometriosis stage I-IV or uterine pathology. Subjects must be willing to not have intake of alcoholic beverages during the study, to not have sexual intercourse during the study, and to either maintain sexual abstinence or use a highly effective method of contraception from end-of-study till onset of next menses.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00587327

Locations
Belgium
UZ Brussel, Center for Reproductive Medicine    
      Brussels, Belgium
Czech Republic
ISCARE IVF a.s.    
      Prague, Czech Republic
Institute for Reproductive Medicine and Endocrinology    
      Pilsen, Czech Republic, 30177
Spain
Institut Universitari Dexeus    
      Barcelona, Spain, 08028
IVI Madrid    
      Madrid, Spain, 28035

Sponsors and Collaborators
Ferring Pharmaceuticals

Investigators
Study Director:     Joan-Carles Arce, MD     Ferring Pharmaceuticals    
  More Information


Responsible Party:   Ferring Pharmaceuticals A/S, Copenhagen ( Joan-Carles Arce, MD, Vice President Clinical Research & Development Obstetrics & Gynaecology )
Study ID Numbers:   FE 200440 CS09
First Received:   December 21, 2007
Last Updated:   June 4, 2008
ClinicalTrials.gov Identifier:   NCT00587327
Health Authority:   Belgium: Ministry of Social Affairs, Public Health and the Environment;   Czech Republic: State Institute for Drug Control

Study placed in the following topic categories:
Arginine Vasopressin
Progesterone
Vasopressins
RWJ 22164
Oxytocin

Additional relevant MeSH terms:
Coagulants
Oxytocics
Hormone Antagonists
Hematologic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Cardiovascular Agents
Reproductive Control Agents
Hemostatics
Pharmacologic Actions
Tocolytic Agents
Natriuretic Agents
Therapeutic Uses
Vasoconstrictor Agents
Antidiuretic Agents

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers